$KYNB News

Oppenheimer Initiates Coverage On Kyntra Bio with Outperform Rating, Announces Price Target of $35

Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes

Kyntra Bio Presents New Data For Roxadustat Showing Improvements In Transfusion Independence Regardless Of Ring Sideroblast Status In Anemia Patients

Rodman & Renshaw Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $30

Kyntra Bio Inc (KYNB) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic Advances ...

Kyntra Bio (KYNB) Q1 2026 Earnings Transcript

Kyntra Bio (KYNB) Reports Q1 Loss, Tops Revenue Estimates

Kyntra Bio (NASDAQ:KYNB) Q1 Revenue Surges 180% as EPS Miss Tempers After-Hours Gains

Kyntra Bio, Inc. (KYNB) Q1 2026 Earnings Call Transcript

Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update

Kyntra Bio, Inc. 2026 Q1 - Results - Earnings Call Presentation

Kyntra Bio Q1 EPS $(3.76) Down From $1.15 YoY, Sales $3.738M Up From $2.739M YoY

Kyntra Bio to Report First Quarter 2026 Financial Results

Kyntra Bio (KYNB) Upgraded to Buy: Here's What You Should Know

RedChip's April 16 Virtual Investor Conference to Highlight Companies Driving the Next Wave of Biotech Innovation

Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference

Kyntra Bio Inc (KYNB) Q4 2025 Earnings Call Highlights: Navigating Revenue Decline with ...

Kyntra Bio (KYNB) Q4 2025 Earnings Call Transcript

Kyntra Bio: Q4 Earnings Snapshot

Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update